EDAP TMS presents 10-year experience results for prostate cancer treatment

By Lisa Kerner

Erie, Pa., April 7 - EDAP TMS SA presented a 10-year European review of Ablatherm-HIFU treatment results during the European Association of Urology meeting in Paris.

EDAP TMS said Ablatherm-HIFU is fully accepted as a treatment for localized prostate cancer, offering a minimally invasive solution for patients with localized prostate cancer who cannot undergo surgery or fail radiotherapy.

Over the past 10 years, EDAP has reduced the average treatment times to 95 minutes following the introduction of an advanced imaging head. The company also introduced nerve sparing applications that can preserve potency in up to 85% of patients using this option, according to a company news release.

"These results confirm Ablatherm-HIFU is the most clinically advanced HIFU choice in treating localized prostate cancer with excellent success, lower side effects and better preservation of the patient's quality of life," chief executive officer Hugues de Bantel said in the release.

"The studies also show Ablatherm-HIFU is fully capable of providing a curative treatment choice for even patients in some of the most clinically difficult situations of recurrence post radiation, where medical professionals are often at an impasse of curative therapy."

Paris, France-based EDAP develops and markets Ablatherm, a High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.